Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1995 Aug;39(8):1835–1841. doi: 10.1128/aac.39.8.1835

Pharmacokinetics and bioavailability of fluconazole in two groups of males with human immunodeficiency virus (HIV) infection compared with those in a group of males without HIV infection.

S Tett 1, S Moore 1, J Ray 1
PMCID: PMC162835  PMID: 7486928

Abstract

Fluconazole pharmacokinetics, including absolute bioavailability, were determined for one group of controls (n = 10) and two groups of people with human immunodeficiency virus (HIV) infection (those with CD4+ T-cell counts of less than [n = 4] or greater than [n = 9] 200 cells per mm3). Twenty subjects received four doses of fluconazole; three doses were oral (50, 100, and 400 mg), and one dose was intravenous (either 50, 100, or 400 mg). The other three subjects received one or two doses. The groups were comparable in terms of the weight, body mass index, and estimated creatinine clearance of the subjects, but the people with HIV infection were older. Pharmacokinetic parameters indicated linearity in all subjects; the area under the plasma concentration-time curve and the maximum concentration increased in proportion to the dose. The fraction of an oral dose of fluconazole absorbed approximated unity in all three groups of subjects. The mean (+/- standard deviation) plasma clearance of fluconazole was lowest in the group of subjects with low CD4+ T-cell counts; the value for this group was 0.74 +/- 0.19 liter/h, compared with 0.97 +/- 0.19 liter/h in the group with HIV infection and CD4+ T-cell counts of greater than 200 cells/mm3 and 1.18 +/- 0.23 liter/h in the group of control subjects (P < 0.05). The volume of distribution was lower in those with HIV infection (P = 0.04, corrected for weight). The half-life was longest in people with HIV infection and low CD4+ T-cell counts (P = 0.01). This study has shown that some differences do exist between the pharmacokinetics of fluconazole in people with HIV infection and those in noninfected controls.

Full Text

The Full Text of this article is available as a PDF (252.0 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Barone J. A., Koh J. G., Bierman R. H., Colaizzi J. L., Swanson K. A., Gaffar M. C., Moskovitz B. L., Mechlinski W., Van de Velde V. Food interaction and steady-state pharmacokinetics of itraconazole capsules in healthy male volunteers. Antimicrob Agents Chemother. 1993 Apr;37(4):778–784. doi: 10.1128/aac.37.4.778. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Blum R. A., D'Andrea D. T., Florentino B. M., Wilton J. H., Hilligoss D. M., Gardner M. J., Henry E. B., Goldstein H., Schentag J. J. Increased gastric pH and the bioavailability of fluconazole and ketoconazole. Ann Intern Med. 1991 May 1;114(9):755–757. doi: 10.7326/0003-4819-114-9-755. [DOI] [PubMed] [Google Scholar]
  3. Bourgoignie J. J. Renal complications of human immunodeficiency virus type 1. Kidney Int. 1990 Jun;37(6):1571–1584. doi: 10.1038/ki.1990.151. [DOI] [PubMed] [Google Scholar]
  4. Chin T., Fong I. W., Vandenbroucke A. Pharmacokinetics of fluconazole in serum and cerebrospinal fluid in a patient with AIDS and cryptococcal meningitis. Pharmacotherapy. 1990;10(4):305–307. [PubMed] [Google Scholar]
  5. Cockcroft D. W., Gault M. H. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31–41. doi: 10.1159/000180580. [DOI] [PubMed] [Google Scholar]
  6. Daneshmend T. K., Warnock D. W. Clinical pharmacokinetics of ketoconazole. Clin Pharmacokinet. 1988 Jan;14(1):13–34. doi: 10.2165/00003088-198814010-00002. [DOI] [PubMed] [Google Scholar]
  7. DeMuria D., Forrest A., Rich J., Scavone J. M., Cohen L. G., Kazanjian P. H. Pharmacokinetics and bioavailability of fluconazole in patients with AIDS. Antimicrob Agents Chemother. 1993 Oct;37(10):2187–2192. doi: 10.1128/aac.37.10.2187. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Debruyne D., Ryckelynck J. P., Bigot M. C., Moulin M. Determination of fluconazole in biological fluids by capillary column gas chromatography with a nitrogen detector. J Pharm Sci. 1988 Jun;77(6):534–535. doi: 10.1002/jps.2600770615. [DOI] [PubMed] [Google Scholar]
  9. Debruyne D., Ryckelynck J. P. Clinical pharmacokinetics of fluconazole. Clin Pharmacokinet. 1993 Jan;24(1):10–27. doi: 10.2165/00003088-199324010-00002. [DOI] [PubMed] [Google Scholar]
  10. Forsmark C. E. AIDS and the gastrointestinal tract. Postgrad Med. 1993 Feb;93(2):143-8, 151-2. doi: 10.1080/00325481.1993.11701605. [DOI] [PubMed] [Google Scholar]
  11. Gatti G., Flaherty J., Bubp J., White J., Borin M., Gambertoglio J. Comparative study of bioavailabilities and pharmacokinetics of clindamycin in healthy volunteers and patients with AIDS. Antimicrob Agents Chemother. 1993 May;37(5):1137–1143. doi: 10.1128/aac.37.5.1137. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Grant S. M., Clissold S. P. Fluconazole. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial and systemic mycoses. Drugs. 1990 Jun;39(6):877–916. doi: 10.2165/00003495-199039060-00006. [DOI] [PubMed] [Google Scholar]
  13. Milatovic D., Voss A. Efficacy of fluconazole in the treatment of systemic fungal infections. Eur J Clin Microbiol Infect Dis. 1992 May;11(5):395–402. doi: 10.1007/BF01961853. [DOI] [PubMed] [Google Scholar]
  14. Revell P., O'Doherty M. J., Tang A., Savidge G. F. Folic acid absorption in patients infected with the human immunodeficiency virus. J Intern Med. 1991 Sep;230(3):227–231. doi: 10.1111/j.1365-2796.1991.tb00435.x. [DOI] [PubMed] [Google Scholar]
  15. Sugar A. M. Treatment of fungal infections in patients infected with the human immunodeficiency virus. Pharmacotherapy. 1990;10(6 ):154S–158S. [PubMed] [Google Scholar]
  16. Toon S., Ross C. E., Gokal R., Rowland M. An assessment of the effects of impaired renal function and haemodialysis on the pharmacokinetics of fluconazole. Br J Clin Pharmacol. 1990 Feb;29(2):221–226. doi: 10.1111/j.1365-2125.1990.tb03623.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Unadkat J. D., Agosti J. M. Problems in pharmacokinetic investigations in patients with HIV infection. Clin Pharmacokinet. 1990 Sep;19(3):172–176. doi: 10.2165/00003088-199019030-00002. [DOI] [PubMed] [Google Scholar]
  18. Van Der Meer J. W., Keuning J. J., Scheijgrond H. W., Heykants J., Van Cutsem J., Brugmans J. The influence of gastric acidity on the bio-availability of ketoconazole. J Antimicrob Chemother. 1980 Jul;6(4):552–554. doi: 10.1093/jac/6.4.552. [DOI] [PubMed] [Google Scholar]
  19. Yamaoka K., Nakagawa T., Uno T. Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equations. J Pharmacokinet Biopharm. 1978 Apr;6(2):165–175. doi: 10.1007/BF01117450. [DOI] [PubMed] [Google Scholar]
  20. Yeates R. A., Ruhnke M., Pfaff G., Hartmann A., Trautmann M., Sarnow E. The pharmacokinetics of fluconazole after a single intravenous dose in AIDS patients. Br J Clin Pharmacol. 1994 Jul;38(1):77–79. doi: 10.1111/j.1365-2125.1994.tb04325.x. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES